Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

AbbVie | DeutschlandAbbVie | Deutschland
VS
Dr. Reddy's LaboratoriesDr. Reddy's Laboratories
AbbVie | Deutschland

AbbVie | Deutschland

Mainzer Straße 81, Wiesbaden, Hessen, DE, 65189

Last Update: 04/03/2026

View Profile
Between 750 and 799
https://www.abbvie.de
754/1000Fair

AbbVie ist ein forschendes BioPharma-Unternehmen, in Deutschland mit rund 3.500 Mitarbeiter*innen an seinem Hauptsitz in Wiesbaden und seinem Forschungs- und Produktionsstandort in Ludwigshafen vertreten. Unsere Mission ist es, innovative Therapien zu erforschen, die e...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:None
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
0
Dr. Reddy's Laboratories

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TS, IN, 500034

Last Update: 03/04/2026

View Profile
Between 750 and 799
http://www.drreddys.com
783/1000Fair

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including AP...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:31,653
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Ranges Comparison

Based On Specific Ai Models Category
AbbVie | Deutschland

AbbVie | Deutschland

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
Dr. Reddy's Laboratories

Dr. Reddy's Laboratories

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AbbVie | Deutschland in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Dr. Reddy's Laboratories in 2026.

Incidents

Incident History - AbbVie | Deutschland (X = Date, Y = Severity)

AbbVie | Deutschland cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - Dr. Reddy's Laboratories (X = Date, Y = Severity)

Dr. Reddy's Laboratories cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
AbbVie | Deutschland

AbbVie | Deutschland

Incidents
No explicit notable incidents reported.
Dr. Reddy's Laboratories

Dr. Reddy's Laboratories

Incidents
No explicit notable incidents reported.

FAQ

Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one has the best AI Cybersecurity Score ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one has experienced more cyber incidents in the past ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one has experienced more cyber incidents this year ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one has experienced at least one ransomware attack ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one has experienced at least one data breach ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one has experienced at least one targeted cyberattack ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one has experienced at least one vulnerability ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one holds the most compliance certifications ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one holds the fewest compliance certifications ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one has the most subsidiaries ?
Between AbbVie | Deutschland company and Dr. Reddy's Laboratories company, which one has the largest number of employees ?
Between AbbVie | Deutschland and Dr. Reddy's Laboratories, which company holds both SOC 2 Type 1 certifications ?
Between AbbVie | Deutschland and Dr. Reddy's Laboratories, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - AbbVie | Deutschland or Dr. Reddy's Laboratories ?
Which company is PCI DSS compliant - AbbVie | Deutschland or Dr. Reddy's Laboratories ?
Between AbbVie | Deutschland and Dr. Reddy's Laboratories, which company complies with HIPAA regulations for healthcare data ?
Between AbbVie | Deutschland and Dr. Reddy's Laboratories, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-19374
SUMMARY

A security vulnerability has been detected in adafap api-mcp up to 92b9a5d04acfec165c7d4ef852496593aa87be06. This affects the function customAxios of the file app/api/proxy/route.ts of the component Proxy API Endpoint. The manipulation of the argument url leads to server-side request forgery. The attack is possible to be carried out remotely. This product adopts a rolling release strategy to maintain continuous delivery. Therefore, version details for affected or updated releases cannot be specified. The project was informed of the problem early through an issue report but has not responded yet.

PUBLISHED
Date2026-08-09
UPDATED
Date2026-08-09
RISK INFORMATION (Score: 7.3)
CVSS2
Base Score: 7.5
Complexity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
CVSS3
Base Score: 7.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 5.5
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
3.9
CVE-2026-19373
SUMMARY

A weakness has been identified in PhialsBasement KoboldCPP-MCP-Server 1.0.0. Affected by this issue is the function makeRequest of the file src/index.ts of the component BaseConfigSchema. Executing a manipulation of the argument apiUrl can lead to server-side request forgery. It is possible to launch the attack on the local host. The project was informed of the problem early through an issue report but has not responded yet.

PUBLISHED
Date2026-08-09
UPDATED
Date2026-08-09
RISK INFORMATION (Score: 5.3)
CVSS2
Base Score: 4.3
Complexity: LOW
AV:L/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 5.3
Complexity: LOW
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 1.9
Complexity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
1.8
CVE-2026-19372
SUMMARY

A security flaw has been discovered in Handwriting-OCR handwriting-ocr-mcp-server 0.1.0. Affected by this vulnerability is the function fs.readFileSync of the file src/index.ts of the component upload_document. Performing a manipulation of the argument File results in path traversal. Attacking locally is a requirement. The project was informed of the problem early through an issue report but has not responded yet.

PUBLISHED
Date2026-08-09
UPDATED
Date2026-08-09
RISK INFORMATION (Score: 5.3)
CVSS2
Base Score: 4.3
Complexity: LOW
AV:L/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 5.3
Complexity: LOW
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 1.9
Complexity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
1.8
CVE-2026-19371
SUMMARY

A vulnerability was identified in Nikolaibibo claude-comfyui-mcp 1.0.0. Affected is the function copyFileSync of the file src/tools/utils.ts of the component comfy_upload_image. Such manipulation of the argument image_path leads to path traversal. An attack has to be approached locally. The project was informed of the problem early through an issue report but has not responded yet.

PUBLISHED
Date2026-08-09
UPDATED
Date2026-08-09
RISK INFORMATION (Score: 5.3)
CVSS2
Base Score: 4.3
Complexity: LOW
AV:L/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 5.3
Complexity: LOW
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 1.9
Complexity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
1.8
CVE-2026-12372
SUMMARY

A Server-Side Request Forgery (SSRF) vulnerability exists in nltk/nltk versions 3.9.4 and the current develop branch. The `nltk.pathsec.validate_network_url()` function, intended to prevent SSRF by rejecting internal network addresses, fails to reject IPs in the RFC 6598 shared address space (`100.64.0.0/10`). This occurs because Python's `ipaddress` module does not classify such addresses as `is_private` or `is_global`, and the current guard only checks `is_private` and a few explicit categories. An attacker who can influence a URL passed to NLTK's network-loading helpers can exploit this vulnerability to make a strict-mode application send requests to shared-address-space hosts, potentially exposing non-public infrastructure reachable from the application host. The impact is limited to SSRF-style confidentiality exposure, with no code execution claimed.

PUBLISHED
Date2026-08-09
UPDATED
Date2026-08-09
RISK INFORMATION (Score: 3.7)
CVSS3
Base Score: 3.7
Complexity: HIGH
CVSS:3.0/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.2